Experts in the News: Barzilai, Kaeberlein, and Kritchevsky in Kaiser Health News on need for clinical trials for drugs that target aging and disease at once
On March 6, 2019, Kaiser Health News featured AFAR experts Nir Barzilai, MD, Matt Kaeberlein, PhD, and Steve Kritchevsky, PhD in an article comparing the state of clinical trials for aging-targeting drugs and rising trends in consumer experimentation with these medications.
Backed by testimony from these AFAR experts as well as experts from the National Institute of Aging, NIH, the article explains the need for rigorous clinical trials–such as the momentum of AFAR-managed Targeting Aging with Metformin (TAME) Trial--to provide proof-of-concept that safe, cost-effective drugs such as metformin and rapamycin can delay the onset of aging and age-related diseases.
Dr. Barzilai is AFAR’s Deputy Scientific Director, multiple grantee, and Director of the Nathan Shock Center of Excellence in the Biology of Aging at Albert Einstein College of Medicine, for which AFAR serves at Coordinating Center.
Dr. Kaeberlein is a 2007 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient and Co-Director of the Nathan Shock Center of Excellence in the Biology of Aging at the University of Washington, for which AFAR serves at Coordinating Center.
Dr. Kritchevsky is the Co-Principal Investigator of the Research Centers Collaborative Network of the National Institute of Aging, NIH, which AFAR also manages. Dr. Kritchevsky is also the Co-PI of the TAME Trial’s Clinical and Multi-Center studies.